Bicycle Therapeutics Ltd ADR 2026年季度报告

Bicycle Therapeutics plc(Exact Name of Registrant as Specified in its Charter) Registrant’s telephone number, including area code:+44 1223 261503 NameofeachexchangeonwhichregisteredThe Nasdaq Stock Market LLC Ordinary shares, nominal value £0.01 per share*American Depositary Shares, each representingone ordinary share, nominal value £0.01 pershare *Not for trading, but only in connection with the listing of the American Depositary Shares on the Nasdaq Global Select Market. and (2)has been subject to such filing requirements for the past 90days.Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrantwas required to submit such files). Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Acceleratedfiler◻Smallerreportingcompany⌧Emerginggrowthcompany◻ Largeacceleratedfiler◻Non-accelerated filer⌧ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No⌧ As of April 27, 2026, the registrant had 50,373,281 ordinary shares, nominal value £0.01 per share, and 19,437,944 non-voting ordinary shares, nominal value £0.01 per share, outstanding. Table of Contents PagePARTI- FINANCIAL INFORMATION1Item1.Financial Statements (unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations and Comprehensive Loss2Condensed Consolidated Statements of Shareholders’ Equity3Condensed Consolidated Statements of Cash Flows4Notesto Condensed Consolidated Financial Statements5Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations22Item3.Quantitative and Qualitative Disclosure About Market Risk33Item4. Controls and Procedures34PARTII- OTHER INFORMATION35Item1.Legal Proceedings35Item1A.Risk Factors35Item2.Unregistered Sales of Equity Securities and Use of Proceeds94Item3.Defaults Upon Senior Securities94Item4.Mine Safety Disclosures94Item5. Other Information94Item6. Exhibits95SIGNATURES SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form10-Q, or this Quarterly Report, contains forward-lookingstatements which are made pursuant to the safe harbor provisions of Section27A of the Securities Act of1933, as amended, or the Securities Act, and Section21E of the Securities Exchange Act of 1934, asamended, or the Exchange Act. These statements may be identified by such forward-looking terminologyas “will,” “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,”“predicts,” “potential,” “continue” or variations of these words or similar expressions that are intended toidentify forward-looking statements, although not all forward-looking statements contain these words. Anyforward-looking statement involves known and unknown risks, uncertainties and other factors that maycause our actual results, levels of activity, performance or achievements to differ materially from anyfuture results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact,about, among other things: ●the initiation, timing, progress and results of our preclinical studies and clinical trials, and ourresearch and development programs;●our ability to advance our product candidates into, and successfully complete, clinical trials;●our reliance on the success of our product candidates in our pipeline programs for ourBicycle®Drug Conjugate, or BDC®molecules, and Bicycle Radioconjugates, or BRC®molecules, as well as our other pipeline programs;●our ability to utilize our screening platform to identify and advance additional productcandidates into clinical development;●the timing or likelihood of regulatory filings and approvals, including communications withand feedback from the FDA and other regulatory agencies;●the commercialization of our product candidates, if approved;●our ability to develop sales and marketing capabilities;●the pricing, coverage and reimbursement of our product candidates, if approved;●the implementation of our business model, strategic plans for our business, productcandidates and technology;●the scope of protection we are able to establish and maintain for intellectual